Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly mo… Read more
Aligos Therapeutics Inc (ALGS) - Net Assets
Latest net assets as of September 2025: $71.83 Million USD
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has net assets worth $71.83 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.76 Million) and total liabilities ($37.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $71.83 Million |
| % of Total Assets | 65.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | -71.01% |
| 10-Year Change | N/A |
| Growth Volatility | 48.27 |
Aligos Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Aligos Therapeutics Inc from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $53.55 Million | +284.81% |
| 2024-12-31 | $-28.97 Million | -131.47% |
| 2023-12-31 | $92.08 Million | -11.38% |
| 2022-12-31 | $103.90 Million | -43.76% |
| 2021-12-31 | $184.73 Million | -16.05% |
| 2020-12-31 | $220.04 Million | +439.09% |
| 2019-12-31 | $-64.89 Million | -372.00% |
| 2018-12-31 | $-13.75 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aligos Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 62826800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | 0.02% |
| Other Comprehensive Income | $468.00K | 0.87% |
| Other Components | $695.27 Million | 1298.48% |
| Total Equity | $53.55 Million | 100.00% |
Aligos Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aligos Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
POZNANSKA K.BUD.P. A ZY1
F:20W
|
$25.07 Million |
|
Isrotel -L
TA:ISRO
|
$25.08 Million |
|
Yoosung T&S Co. Ltd
KQ:024800
|
$25.08 Million |
|
Forward Graphic Enterprise Co Ltd
TWO:8906
|
$25.08 Million |
|
Hongkong Chinese Limited
F:HKC
|
$25.06 Million |
|
Infrea AB
ST:INFREA
|
$25.06 Million |
|
GavYam Lands Corp Ltd
TA:GVYM
|
$25.05 Million |
|
ZK International Group Co Ltd
NASDAQ:ZKIN
|
$25.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aligos Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -28,973,000 to 53,545,000, a change of 82,518,000.
- Net loss of 24,193,000 reduced equity.
- Other comprehensive income increased equity by 17,000.
- Other factors increased equity by 106,694,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.19 Million | -45.18% |
| Other Comprehensive Income | $17.00K | +0.03% |
| Other Changes | $106.69 Million | +199.26% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aligos Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.65 | $6.95 | x |
| 2019-12-31 | $-2.96 | $6.95 | x |
| 2020-12-31 | $6.44 | $6.95 | x |
| 2021-12-31 | $4.64 | $6.95 | x |
| 2022-12-31 | $2.43 | $6.95 | x |
| 2023-12-31 | $3.70 | $6.95 | x |
| 2024-12-31 | $-4.62 | $6.95 | x |
| 2025-12-31 | $5.42 | $6.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aligos Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.65x
- Recent ROE (-45.18%) is below the historical average (-43.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.56 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-45.77 Million |
| 2020 | -49.33% | 0.00% | -0.04x | 1.21x | $-130.55 Million |
| 2021 | -69.47% | -2944.07% | 0.02x | 1.27x | $-146.81 Million |
| 2022 | -92.44% | -690.63% | 0.09x | 1.41x | $-106.44 Million |
| 2023 | -95.22% | -564.61% | 0.10x | 1.65x | $-96.89 Million |
| 2024 | 0.00% | -3326.01% | 0.06x | 0.00x | $-128.31 Million |
| 2025 | -45.18% | 0.00% | 0.00x | 1.65x | $-29.55 Million |
Industry Comparison
This section compares Aligos Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aligos Therapeutics Inc (ALGS) | $71.83 Million | 0.00% | 0.53x | $25.07 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |